These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
462 related items for PubMed ID: 30417422
1. Inactivation of ADAMTS18 by aberrant promoter hypermethylation contribute to lung cancer progression. Zhang Y, Xu H, Mu J, Guo S, Ye L, Li D, Peng W, He X, Xiang T. J Cell Physiol; 2019 May; 234(5):6965-6975. PubMed ID: 30417422 [Abstract] [Full Text] [Related]
2. LHX6 acts as a novel potential tumour suppressor with epigenetic inactivation in lung cancer. Liu WB, Jiang X, Han F, Li YH, Chen HQ, Liu Y, Cao J, Liu JY. Cell Death Dis; 2013 Oct 24; 4(10):e882. PubMed ID: 24157876 [Abstract] [Full Text] [Related]
3. KRAB zinc-finger protein 382 regulates epithelial-mesenchymal transition and functions as a tumor suppressor, but is silenced by CpG methylation in gastric cancer. Pei L, He X, Li S, Sun R, Xiang Q, Ren G, Xiang T. Int J Oncol; 2018 Sep 24; 53(3):961-972. PubMed ID: 29956735 [Abstract] [Full Text] [Related]
4. Remodeling epigenetic modifications at tumor suppressor gene promoters with bovine oocyte extract. Wang Z, Yue Y, Han P, Sa R, Ren X, Wang J, Bai H, Yu H. Cytotherapy; 2013 Sep 24; 15(9):1164-73. PubMed ID: 23800731 [Abstract] [Full Text] [Related]
5. The 3p14.2 tumour suppressor ADAMTS9 is inactivated by promoter CpG methylation and inhibits tumour cell growth in breast cancer. Shao B, Feng Y, Zhang H, Yu F, Li Q, Tan C, Xu H, Ying J, Li L, Yang D, Peng W, Tang J, Li S, Ren G, Tao Q, Xiang T. J Cell Mol Med; 2018 Feb 24; 22(2):1257-1271. PubMed ID: 29193730 [Abstract] [Full Text] [Related]
7. The new 6q27 tumor suppressor DACT2, frequently silenced by CpG methylation, sensitizes nasopharyngeal cancer cells to paclitaxel and 5-FU toxicity via β-catenin/Cdc25c signaling and G2/M arrest. Zhang Y, Fan J, Fan Y, Li L, He X, Xiang Q, Mu J, Zhou D, Sun X, Yang Y, Ren G, Tao Q, Xiang T. Clin Epigenetics; 2018 Feb 27; 10(1):26. PubMed ID: 30359298 [Abstract] [Full Text] [Related]
8. MTSS1 hypermethylation is associated with prostate cancer progression. Chen J, Huang L, Zhu Q, Wang Z, Tang Z. J Cell Physiol; 2020 Mar 27; 235(3):2687-2697. PubMed ID: 31541465 [Abstract] [Full Text] [Related]
14. Down-regulation of dual-specificity phosphatase 5 in gastric cancer by promoter CpG island hypermethylation and its potential role in carcinogenesis. Shin SH, Park SY, Kang GH. Am J Pathol; 2013 Apr 27; 182(4):1275-85. PubMed ID: 23402999 [Abstract] [Full Text] [Related]
15. Protocadherin-10 acts as a tumor suppressor gene, and is frequently downregulated by promoter methylation in pancreatic cancer cells. Qiu C, Bu X, Jiang Z. Oncol Rep; 2016 Jul 27; 36(1):383-9. PubMed ID: 27176920 [Abstract] [Full Text] [Related]
16. Epigenetic inactivation of HOXD10 is associated with human colon cancer via inhibiting the RHOC/AKT/MAPK signaling pathway. Yuan YH, Wang HY, Lai Y, Zhong W, Liang WL, Yan FD, Yu Z, Chen JK, Lin Y. Cell Commun Signal; 2019 Jan 25; 17(1):9. PubMed ID: 30683109 [Abstract] [Full Text] [Related]
19. Epigenetic silencing of miR-493 increases the resistance to cisplatin in lung cancer by targeting tongue cancer resistance-related protein 1(TCRP1). Gu Y, Zhang Z, Yin J, Ye J, Song Y, Liu H, Xiong Y, Lu M, Zheng G, He Z. J Exp Clin Cancer Res; 2017 Aug 31; 36(1):114. PubMed ID: 28859669 [Abstract] [Full Text] [Related]
20. Protocadherin 10 is frequently downregulated by promoter methylation and functions as a tumor suppressor gene in non-small cell lung cancer. Tang X, Yin X, Xiang T, Li H, Li F, Chen L, Ren G. Cancer Biomark; 2017 Aug 31; 12(1):11-9. PubMed ID: 23321465 [Abstract] [Full Text] [Related] Page: [Next] [New Search]